Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lumasiran (ALN-G01), a siRNAproduct, targets glycolate oxidase to inhibit hepatic oxalate production. By silencing the gene encoding glycolate oxidase, Lumasiran depletes the enzyme, preventing the synthesis of oxalate, a toxic metabolite directly linked to the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $813 | Backorder | |
5 mg | $1,990 | Backorder | |
10 mg | $3,230 | Backorder |
Description | Lumasiran (ALN-G01), a siRNAproduct, targets glycolate oxidase to inhibit hepatic oxalate production. By silencing the gene encoding glycolate oxidase, Lumasiran depletes the enzyme, preventing the synthesis of oxalate, a toxic metabolite directly linked to the clinical manifestations of Primary hyperoxaluria type 1 (PH1). |
In vitro | Lumasiran effectively decreased the excretion of urinary oxalate, which is responsible for the progression of kidney failure in patients with Primary Hyperoxaluria Type 1 (PH1)[1]. |
In vivo | Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent[2]. |
Alias | ALN-G01 |
Cas No. | 1834610-13-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.